# The Netherlands Cancer Institute: Phase 1 study started recruiting, 20 planned (Lung Cancer (NSCLC), HER2 Expression)

**Score:** 35/100

| Field | Value |
|---|---|
| Sponsor | The Netherlands Cancer Institute |
| Sponsor type | Academic and hospital |
| Study | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer |
| NCT ID | NCT07436858 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Lung Cancer (NSCLC); HER2 Expression; HER2 Gene Mutation |
| Intervention types | diagnostic test |
| Target enrollment | 20 |
| Site countries | Netherlands |
| Posted | 2026-02-27 |
| Planned start | 2026-10-02 |
| Event | Started recruiting |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-20 |

## Why this score
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07436858). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.